Zacks Investment Research upgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a sell rating to a hold rating in a research note published on Wednesday morning.
According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “
A number of other brokerages have also recently weighed in on AQST. Wedbush raised their price objective on shares of Aquestive Therapeutics from $29.00 to $30.00 and gave the stock an outperform rating in a research note on Thursday, December 6th. Royal Bank of Canada set a $24.00 price objective on shares of Aquestive Therapeutics and gave the stock a buy rating in a research note on Wednesday, November 7th. Finally, Lake Street Capital reissued a buy rating on shares of Aquestive Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Aquestive Therapeutics currently has a consensus rating of Buy and a consensus price target of $24.25.
Shares of AQST traded down $0.46 during mid-day trading on Wednesday, reaching $5.85. 34,639 shares of the company’s stock were exchanged, compared to its average volume of 94,650. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.63 and a quick ratio of 3.42. Aquestive Therapeutics has a 52-week low of $5.60 and a 52-week high of $20.70.
In other news, CEO Keith J. Kendall bought 7,950 shares of the firm’s stock in a transaction that occurred on Friday, November 23rd. The shares were purchased at an average price of $10.10 per share, for a total transaction of $80,295.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John T. Maxwell bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 6th. The shares were purchased at an average price of $8.87 per share, for a total transaction of $44,350.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 17,450 shares of company stock worth $165,065.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund acquired a new stake in Aquestive Therapeutics during the fourth quarter worth approximately $28,000. Bank of New York Mellon Corp acquired a new stake in Aquestive Therapeutics during the fourth quarter worth approximately $108,000. Millennium Management LLC acquired a new stake in Aquestive Therapeutics during the fourth quarter worth approximately $145,000. Squarepoint Ops LLC acquired a new stake in Aquestive Therapeutics during the fourth quarter worth approximately $188,000. Finally, Keybank National Association OH acquired a new stake in Aquestive Therapeutics during the third quarter worth approximately $239,000. Hedge funds and other institutional investors own 66.47% of the company’s stock.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Read More: Understanding Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.